Big-deal Gilead rheumatoid arthritis drug rejected by FDA

A rheumatoid arthritis drug at the center of Gilead Sciences Inc.'s big collaboration with Belgian drugmaker Galapagos NV has been rejected by the Food and Drug Administration. The Foster City-based company (NASDAQ: GILD) said late Tuesday that the FDA requested more data from two studies before completing its review of Gilead's filgotinib as a treatment for moderately to severely active rheumatoid arthritis. The agency also "expressed concerns," the company said, about the overall benefit-risk…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news